Click here to view or download the IPCU 2019 Poster Abstract Booklet

Click the title of a poster below to open or download presentation slides in PDF format.

19-001
Association of Dose Reduction of Abiraterone Acetate plus Prednisone or Enzalutamide and PSA Progression in Veterans with Metastatic Castration Resistant Prostate Cancer

19-002
The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) > 1.5 Improves the Detection of Clinically Significant Cancers in Men Undergoing Transperineal Biopsy of the Prostate

19-003
Late Administration of Luteinizing Hormone-Releasing Hormone Agonists and Testosterone Levels >50 Ng/Dl In Prostate Cancer

19-004
Biopsy-Derived Cell Cycle Progression Score Outperforms Pathologic Upgrading or Upstaging in Predicting Biochemical Recurrence After Surgery

19-005
Patient Valuation of Castration-Resistant Prostate Cancer Health States

19-006
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

19-007
Cardiometabolic Effects Associated with Androgen Deprivation Therapy: Potential Mechanisms of Action

19-008
Genomic Profiling of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) for the Evaluation of Rucaparib: Next-Generation Sequencing (NGS) of Tumor Tissue and Cell-Free DNA (cfDNA)

19-009
Phase 3 HERO Study Design: Evaluation of the Safety and Efficacy of Relugolix, a Novel Oral GnRH Receptor Antagonist, in Men with Advanced Prostate Cancer

19-010
Impact of Positron Emission Tomography with 18F-Fluciclovine on Management of Patients in the United States with Biochemically Recurrent Prostate Cancer: Results from the LOCATE Trial

19-011
Men with PIRADS Score ≤ 3 and SelectMDx Score ≤ 30% can be Spared from Prostate Biopsy

19-012
Comparison of SelectMDx, Prostate Health Index, and MRI for Diagnosis of High-Grade Prostate Cancer

19-013
Clinical Utility of SelectMDx and Prostate Health Index Tests for Diagnosis of High-Grade Prostate Cancer

19-014
Clinical Experience with a DNA Specimen Provenance Assay

19-015
Real-World Study of Enzalutamide and Abiraterone Acetate (with Prednisone)

ABOUT THE AUTHOR

David Utz